Global Liquid Biopsy Market

1
Global Liquid Biopsy Market
Category Diagnostics Market Report
2
Global Liquid Biopsy Market Analyst View
Liquid Biopsy Market is projected to exceed US
3.4 Billion by the year 2024. Get Free
Customization in this Report Press Release
Title Liquid Biopsy Market is projected to
surpass US 3.4 Billion by 2024.   For more Info
https//www.renub.com/global-liquid-biopsy-market
-nd.php

3
Liquid Biopsy Market is projected to surpass US
3.4 Billion by the end of year 2024.
Research Report Title Liquid Biopsy Market,
Global Analysis by Cancer (Lung Cancer, Breast
Cancer, Colorectal Cancer, Prostate Cancer
Others), Product (Kits Consumables, Instruments
and Services), Circulating Biomarkers
(Circulating Tumor Cells (CTCs), Circulating
Tumor DNA (ctDNA) Exosomes), Sample
(Plasma/Serum, Urine Others), Clinical
Application (Monitoring, Prognosis, Theranostics
Screening), Regions (North America, Europe,
Asia-Pacific, Latin America and Middle
East/Africa), Companies (Thermo Fisher Scientific
Inc., Roche Diagnostics, Bio-Rad Laboratories
Inc., Biocept Inc., Biocartis, Myriad Genetics
Inc., Genomic Health, NeoGenomics Laboratories,
Qiagen) Access Full Research https//www.renub.
com/liquid-biopsy-market-p.php

4
Liquid Biopsy Market is projected to surpass US
3.4 Billion by the end of year 2024.
Liquid Biopsy is a non-invasive technology which
is used in the detection of molecular biomarkers
without the need for invasive or costly surgical
procedures. Liquid Biopsy is a simple and an
alternative method to surgical biopsies which
helps physicians to discover a range of
information about a tumor or a disease through a
simple blood, urine, saliva or cerebrospinal
fluids sample. Circulating cancer cells or traces
of the cancers DNA or DNA in the fluid sample
can give indication about the treatments that a
patient likely to need. Liquid Biopsy Market is
projected to surpass US 3.4 Billion by the end
of year 2024.    Increasing Cancer Incidences On
an estimate nearly 14.1 million people suffered
from cancer around the world in 2012, of
which 7.4 million were men and 6.7 million women.
The incidence of cancer seems to be increasing
with increasing per capita income. Asia, Europe
and Americas are some of the regions where
highest incidences of cancer occur. Lung Cancer,
Colorectal Cancer and Breast Cancer are among the
most prevalent types of cancer worldwide.

5
Liquid Biopsy Market is projected to surpass US
3.4 Billion by the end of year 2024.

6
Liquid Biopsy Market is projected to surpass US
3.4 Billion by the end of year 2024.
Request a free sample copy of the
report  https//www.renub.com/contactus.php  Due
to the rising prevalence of cancer and the
complexity of cancers treatment, demand for
liquid biopsy test is increasing more rapidly
during the patients care than ever before. The
liquid biopsy test is basically the analysis of
various analytes, namely Circulating Tumor Cells
(CTCs), Circulating Tumor DNA (ctDNA),
Extracellular Vesicles (Exosomes), miRNA, mRNA
and Proteins. Circulating Tumor Cells (CTCs) and
Circulating Tumor DNA (ctDNA) have been the most
analyzed and commercially developed medical
technologies amongst these analytes. Use of
Liquid Biopsy in Oncology In regards to both
cancer diagnosis and its treatment, liquid biopsy
is one of the most significant techniques.
Personalized or precision medicine is one of the
categories in oncology care which focuses more on
a patients genetic profile to target their
cancer. Regrettably, all cancers are not same and
so, one treatment for all One Size Fits All
may cause more harm than anything good. Using a
liquid biopsy can help determine whether the
ongoing treatment is effective or not. 

7
Liquid Biopsy Market is projected to surpass US
3.4 Billion by the end of year 2024.
Cancerous tumors can be stony by the treatment in
the past. Acquired resistance is one of the major
obstructions in eliminating cancer using drugs
and treatments like radiation, which have huge
side effects. These treatment resistances can
easily be detected using a liquid biopsy test.
Using precision medicine such as genetic
mutations (ctDNA), is a process which can limit
the associated dangers of such treatments.  These
days, patients cancer treatment is shifting
from non-specific, cytotoxic chemotherapy to more
specific, targeted therapies or immunotherapy
which focus more on the precise genetic
characteristics of the patients that are
identified either by liquid biopsy or tissue
methods earlier to or during the cancer
therapy. Also, companies around the world plan
to develop more affordable fluids based (liquid
biopsy) cancer screening tests to detect cancer
in early stages. With the recent advancement in
medical science, it is expected that liquid
biopsy tests will become cost-efficient and will
certainly exert liquid biopsy market to grow
further in the near future. 

8
Liquid Biopsy Market is projected to surpass US
3.4 Billion by the end of year 2024.

• Client can Purchase this Report in Sections from
  below link
• Access full Research https//www.renub.com/liquid
  -biopsy-market-p.php
•  
• Global Liquid Biopsy Market Summary 
• Lung Cancer Controls the Liquid Biopsy Market. On
  the basis of cancer segments report studies the
  market of Lung Cancer, Breast Cancer, Colorectal
  Cancer, Prostate Cancer Others.
• Based on product type 90 of liquid biopsy market
  is comprised by kits Consumables and
  Instruments. The covers the market of Kits
  consumables, Instruments and Services.
• On the basis of Clinical Application Screening
  Purpose controls the Liquid Biopsy Market. The
  study provides the data on the following segments
  Monitoring, Prognosis, Theranostics Screening.
• .

9
Liquid Biopsy Market is projected to surpass US
3.4 Billion by the end of year 2024.

• Region-wise Europe and North America is expected
  to drive the Global Liquid Biopsy Market.
  Asia-Pacific, Latin America and Middle
  East/Africa Liquid Biopsy Markets are also
  studied in the report.
•  On the basis of Sample Plasma/Serum accounts for
  the highest market compared to Urine and Others. 
• The report studies the liquid biopsy market by
  Circulating Tumor Cells (CTCs), Circulating Tumor
  DNA (ctDNA) Exosomes.
• The competitive landscape of the market has also
  been examined with some of the key players being
  Qiagen, Roche Diagnostics, Myriad Genetics, Inc.,
  Thermo Fisher Scientific Inc., Genomic Health,
  Bio-Rad Laboratories Inc., NeoGenomics
  Laboratories, Biocartis and Biocept Inc.,  
• If the information you seek is not included in
  the current scope of the study kindly share your
  specific requirements with our custom research
  team at info_at_renub.com

10
Table of Contents for Global Liquid Biopsy Market
Key Topics Covered 1.    Executive Summary 2.  
 Global - Liquid Biopsy Market 3.    Market
Share Global Liquid Biopsy 3.1    By
Region 3.2    By Cancer3.3    By
Product 3.4    By Circulating Biomarkers 4.   
Region - Liquid Biopsy Market 4.1    North
America 4.2    Europe4.3    Asia-Pacific 4.4  
 Latin America4.5    Middle East Africa 5.  
 Cancer - Liquid Biopsy Market 5.1    Lung
Cancer 5.2    Breast Cancer5.3    Colorectal
Cancer 5.4    Prostate Cancer5.5    Others

11
Table of Contents for Global Liquid Biopsy Market
6.    By Product - Liquid Biopsy Market 6.1  
 Kits Consumables 6.2    Instruments6.3  
 Services 7.    Circulating Biomarkers - Liquid
Biopsy Market 7.1    Circulating Tumor Cells
(CTCs) 7.2    Circulating Tumor DNA (ctDNA)7.3  
 Exosomes 8.    By Clinical Application - Liquid
Biopsy Market 8.1    Monitoring 8.2  
 Prognosis8.3    Theranostics 8.4  
 Screening 9.    By Sample - Liquid Biopsy
Market 9.1    Plasma / Serum 9.2    Urine9.3  
 Others 10.    Thermo Fisher Scientific Inc
Company Analysis 10.1    Product Portfolio

12
Table of Contents for Global Liquid Biopsy Market
11    Roche Diagnostics Company
Analysis 11.1    Product Portfolio 12.  
 Bio-Rad Laboratories Inc Company
Analysis 12.1    Product Portfolio 13.  
 Biocept, Inc. Company Analysis 13.1    Product
Portfolio 13.2    Financial Insight 14.  
 Biocartis Company Analysis 14.1    Product
Portfolio 14.2    Financial Insight 15.  
 Myriad Genetics, Inc Company Analysis 15.1  
 Product Portfolio 15.2    Financial
Insight 16.    Genomic Health Company
Analysis 16.1    Product Portfolio 16.2  
 Financial Insight

13
Table of Contents for Global Liquid Biopsy Market
17.    NeoGenomics Laboratories Company
Analysis 17.1    Product Portfolio 17.2  
 Financial Insight 18.    Qiagen Company
Analysis 18.1    Product Portfolio18.2  
 Financial Insight 19.    Growth Drivers 19.1  
 Real-Time Evaluation, Convenient and
Accuracy19.2    Increasing Demand for
Minimally-Invasive Biopsy Techniques19.3  
 Technical Advancement Personalized
Therapies 20.    Challenges 20.1    Barriers for
Liquid Biopsies20.2    High Cost with Uncertain
or Limited Reimbursement for Liquid Biopsy

14
Get Free Customization in this Report
Diagnostics Market Reports https//www.renub.
com/diagnostics-14-c.php
Renub Research - North America Rajat Gupta 225 Kristie Ln, Roswell Georgia 30076, United States Tel [phone] Email info_at_renub.com www.renub.com Renub Research - Asia Ankit Mishra C 86, Sector 10 Noida 201301, India Tel [phone] Email info_at_renub.com www.renub.com